9 results about "Inflammatory genes" patented technology

This disclosure provides a method for treating a cancer patient comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antagonist, for example, an anti-PD-1 or anti-PD-L1 antibody, in combination with an indolamine 2,3-dioxygenase inhibitor, wherein the patient is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ-related inflammatory genes in a cancer sample obtained from the patient, wherein the gene panel comprises, for example, IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some respects, the gene panel also includes CCR5, CXCL11, GZMA, and PRF1.In some aspects, the genetic panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E and TDO2.

The invention belongs to the field of bioengineering and neurotoxicity prevention and control, and particularly relates to a neurotoxicity antagonist screening and evaluating method based on a microorganism-intestine-brain axis. The screening method of the neurotoxicity antagonist comprises the following steps: establishment of a neurotoxicity animal model, verification of the neurotoxicity model, sequencing of intestinal flora and screening of key flora, coupling analysis of flora-cranial nerve indexes, verification of candidate microorganisms, screening of core bacterial metabolites, verification of the core bacterial metabolites and verification of the core bacterial metabolites. According to the method, through behavior-neurotransmitter-inflammation-gene / mitochondrial function multi-level index linkage, a reproducible recovery index (RI) index is established, and quantitative screening and grading judgment of candidate strains and metabolites of the candidate strains on nerve injury repair are achieved.

The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.

The invention relates to the technical field of biology, and discloses a Lactobacillus paracasei KFY202407 and an application thereof in preparation of a preparation for preventing and treating vaginitis, the collection number of the Lactobacillus paracasei KFY202407 in China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO: 30736, and the collection date is May 22, 2024. The lactobacillus paracasei KFY202407 disclosed by the invention can relieve inflammation of mice with vaginitis by regulating secretion of mouse serum inflammatory factors, activity of vaginal tissue MPO and expression conditions of vaginal tissue inflammatory genes. The microbial inoculum prepared from the lactobacillus paracasei KFY202407 has good stability and can be used as a medicine raw material.

The receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor member of the immunoglobulin super family which is able to bind Aβ peptide and 3-sheet fibrils. It is expressed in endothelial cells, smooth muscle cells, microglia and neurons, and is implicated in the transport of Aβ through the blood-brain barrier (BBB), oxidative stress-mediated neurotoxicity, and adverse microglia inflammatory responses. The interaction between RAGE and its ligands is thought to result in pro-inflammatory gene activation. Enhanced levels of RAGE ligands in Alzheimer's disease are thought to contribute to the cause of this disorder. Embodiments of the invention use the RAGE multi-ligand site as an anchoring loci for a conversion electron emitting compound rather than as a receptor to intrinsically activate or block inflammation through the RAGE intracellular cascade through activation of the RAGE cytoplasmic tail (ctRAGE) and mammalian diaphanous 1 (DIAPH1).

The embodiment of the invention discloses a modeling method of a periodontitis and preeclampsia combined model, which comprises the following steps of: performing first-stage periodontitis modeling on an experimental mouse through continuous orthodontic ligation for 10 days, and performing continuous annular ligation for 10 days on the basis to perform second-stage periodontitis modeling on the experimental mouse, when the expression level of the inflammation gene of the gingival tissue of the experimental mouse is obviously increased, the periodontitis model of the experimental mouse is successfully established. The method comprises the following steps of: performing preeclampsia modeling on the basis of experimental mice of which periodontitis models are successfully established, randomly dividing pregnant female experimental mice into a model group and a control group, and injecting a nitric oxide synthase inhibition solution into the experimental mice in the model group, when the tail artery systolic pressure of the experimental mice in the model group is increased by at least 20mmHg compared with that of the control group and is continuously increased until the end of pregnancy, the periodontitis and preeclampsia combined model of the experimental mice is successfully established, and the model has important academic value and clinical significance for reducing the occurrence rate of complications in the gestation period and improving maternal and fetal prognosis.

The invention discloses an ovarian cancer prognosis analysis method, system and device, and the method comprises the following steps: 1, obtaining case data of an ovarian cancer patient, and removing case data without patient survival information, the case data comprising patient clinical data and ovarian cancer gene expression data; 2, carrying out clustering analysis on the gene expression data and inflammation genes of the ovarian cancer patients meeting the requirements in the step 1, and screening out differentially expressed inflammation related genes; 3, performing univariate Cox regression analysis on the differential gene expression level obtained in the step 2 and the survival rate of the ovarian cancer patient, and screening inflammation-related genes with prognosis value; through multivariable Cox regression analysis, inflammation-related genes with remarkable ovarian cancer prognosis are screened; 4, establishing an ovarian cancer prognosis model based on the ovarian cancer prognosis significant inflammation related genes screened in the step 3; and 5, based on the prognosis model constructed in the step 4, performing prognosis analysis on the case data of the ovarian cancer patient. Through verification, the prognosis model constructed by the invention can be used for prognosis of ovarian cancer patients.

The application belongs to the technical field of new application of medicines, and particularly relates to hydroxycinnamic acid derivatives, a preparation method and application thereof. The ARDS model is induced by LPS tracheal instillation combined with hydroxycinnamic acid derivatives, the alveolar lavage fluid cell count is determined, and the pathological characteristics and the expression level of inflammatory genes of lung tissues are detected; the results show that the hydroxycinnamic acid derivatives can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce the expression level of inflammatory factors.

The application belongs to the technical field of safflower and specifically relates to a safflower extract and a preparation method and application thereof, and the safflower extract is obtained by alcohol extraction of safflower kernel skin, and the content of phenylacryl-5-hydroxytryptamine compounds in the extract is 45%-55%. The content of PAHA in the safflower kernel skin extract provided in the application reaches 50%, SKE has good antioxidant activity, can effectively scavenge free radicals and thus delay the oxidation process; the overall antioxidant capacity of HEK293T cells treated by SKE increases, the ability of scavenging free radicals and scavenging peroxides in the body can be enhanced; SKE can effectively slow down the expression increase of inflammatory genes IL-1alpha, IL-6 and COX2 caused by E. coli; SKE has a significant inhibitory effect on specific growth stages of E. coli and Staphylococcus aureus.